Clinical pathway before travel
An international enquiry is organised around diagnosis, prior treatment, target, product or protocol status, hospital review, and fitness to travel.
China medical tourism · CAR-T · Oncology innovation
China medical tourism for CAR-T and oncology innovation—reviewed with clinical discipline.
We help international patients and their home clinicians examine CAR-T treatment in China and other innovative oncology pathways by exact disease, target, regulatory status, hospital programme, safety system, written cost, and return-home plan.
Exact disease and targetApproved care separated from researchNamed treatment programmeHome-clinician handover
CHINA MEDICAL TOURISM / CAR-T
What China medical tourism means for a CAR-T enquiry.
For HarbourBridge, medical travel is a governed clinical pathway—not a hospital shopping list. The decision starts with evidence, safety, current hospital capability, complete written costs, and a receiving clinician at home.
CAR-T treatment in China is programme-specific
Availability, manufacturing, admission, toxicity rescue, and follow-up must be confirmed for the exact product, indication, hospital site, and date.
Independent navigation, not treatment advice
HarbourBridge coordinates evidence and administration; licensed hospital teams decide diagnosis, eligibility, consent, treatment, and discharge.
CHOOSE A STARTING POINT
Begin with your question—not a hospital package.
Choose the route closest to your situation. It is an information pathway, not a statement of eligibility.
01 / DISEASE GUIDE
Understand blood cancers
Review ten disease groups, diagnostic context, and innovation categories before discussing a product.
Explore this route02 / INTERACTIVE DATACompare CAR-T products
Filter source-dated products and research targets by antigen, disease, and regulatory category.
Explore this route03 / PRIMARY FOCUSHaematology CAR-T
Match the blood cancer, antigen target, product status, programme, rescue capability, and follow-up.
Explore this route04 / STATUS GUIDEUnderstand stem-cell therapies
Separate established transplantation, one narrowly approved medicine, registered research, and unsupported commercial claims.
Explore this route05 / INTERACTIVE DATACompare stem-cell pathways
Filter by cell family, disease group, and evidence status without turning research into treatment matching.
Explore this route06 / INNOVATIONNovel oncology therapies
Review China-origin medicines, cellular therapies, trials, and approved care without blurring their status.
Explore this route07 / SOLID-TUMOUR CAR-TSatri-cel (CT041)
Review the narrow approved indication, biomarker threshold, evidence, hospitals, and product-only price reference.
Explore this route08 / DISCOVERYFind the relevant pathway
Filter pathways, centres, and cost evidence by disease and treatment method.
Explore this routePosition before promotion
Navigation built around clinical authority and transparent limits.
The company coordinates evidence, communication, and logistics. It does not replace the clinicians responsible for diagnosis, consent, treatment, complications, discharge, or fitness to fly.
Treatment is not a product listing
We distinguish approved care, off-label use, registered trials, and investigational pathways. Hospital acceptance and eligibility are never assumed.
Price is not the decision
We compare the defined episode, evidence type, inclusions, exclusions, and current written quote. We do not promise a percentage saving.
Travel does not end responsibility
The journey includes emergency planning, named China support, complete records, and a receiving clinician for follow-up at home.
Primary clinical focus
Haematology CAR-T and oncology innovative therapies come first.
Broader surgery and specialty pathways remain available, but the principal programme is cellular and innovative oncology care reviewed by exact indication, regulatory status, hospital site, named team, toxicity system, treatment duration, price evidence, and home follow-up.
Primary focus01
Haematology CAR-T
Disease subtype, antigen target, product and protocol status, collection, manufacturing, bridging therapy, toxicity rescue, and long-term follow-up.
Haematology CAR-T
Innovation review02
Novel oncology therapies
Selected China-origin medicines, cellular therapies, biomarker-led options, and trials—without presenting research as routine care.
Oncology innovation
Approved solid-tumour CAR-T03
Satri-cel (CT041)
A dedicated evidence, hospital, biomarker, safety, and product-price dossier for its narrowly defined approved population.
Satri-cel
The review sequence
A patient journey with stop gates.
A responsible service must be prepared to recommend no travel. Progress depends on clinical completeness, hospital acceptance, financial clarity, travel readiness, and continuity at home.
Our role
Independent navigation only. We do not diagnose, prescribe, or treat. Hospitals and licensed clinical teams retain every medical decision.
Minimal enquiry
Only broad information is requested. Urgent or unstable patients are directed to local care.
Secure dossier
Detailed records are considered only within a secure, consented workflow—not the public form.
Independent comparison
The proposed route, hospital, risks, alternatives, written costs, and insurance position are compared.
Supported treatment
A named coordinator assists with non-clinical logistics while the hospital leads all care.
Documented return
Discharge records and a responsible receiving clinician are confirmed before case closure.
In-country continuity
A named coordinator in Shanghai or Beijing.
Your coordinator supports appointments, arrival, registration, interpreter arrangements, practical check-ins, invoices, discharge records, and the handover home. A backup coordinator is assigned for continuity.
Organise practical logistics
Coordinate qualified interpretation
Track documents and itemised bills
Escalate concerns to the hospital team
Your coordinator does not
Diagnose or triage
Interpret results independently
Recommend or change treatment
Provide unlicensed nursing care
Cost evidence
Compare like with like—or say that comparison is not possible.
Public figures may be historical hospital costs, radiotherapy components, private packages, cash purchases, public tariffs, or payer amounts. Each example is labelled, and the patient’s current written hospital quote remains controlling.
01Evidence type
02Source date
03Inclusions
04Exclusions
05Written quote required
WHO CHARGES WHAT
Three scopes. Three written confirmations.
Keep navigation, medical, and third-party charges separate; a low headline price is not a comparable episode.
Navigation company
Quoted by HarbourBridgeScope, language, coordination time, exclusions, revision and cancellation terms.
Hospital and clinicians
Quoted and paid directly to providerProcedure, professional fees, devices, admission, medicines, complications and follow-up.
Travel and third parties
Quoted by each supplierFlights, visa administration, accommodation, transport, companions and extended stay.
PLANNING ESSENTIALS
The practical questions belong in the care plan.
Prepare records, permissions, accommodation, payment, companions, and return-home continuity before committing to travel.
01
Prepare records securely
Use the authenticated portal—not email or public chat—for detailed records.
02Visa and accommodation
Ask the source-grounded assistant, then escalate uncertainty to staff.
03Insurance pre-authorisation
Separate policy review, written approval, direct settlement, and patient liability.
04Companion and in-China support
Confirm practical coordination, language support, and non-clinical boundaries.
05Admission to home handover
Know the decision gates, discharge packet, and receiving clinician.
06Verify the treating centre
Check the site, team, licence, equipment, ICU, and rescue route.
AI / ADMINISTRATIVE FAQ
Practical questions, grounded in approved sources.
Ask about visa administration, accommodation logistics, or insurance paperwork—not diagnosis or treatment advice.
Ask the FAQ assistantB2B / CLINICAL
Built for collaboration with home clinicians and insurers.
We prepare structured dossiers, document treatment status, coordinate written estimates and authorisation materials, and return complete handover records.